Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribba, A.
Right arrow Articles by Pietu, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribba, A.
Right arrow Articles by Pietu, G
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease

AS Ribba, O Christophe, A Derlon, G Cherel, V Siguret, JM Lavergne, JP Girma, D Meyer and G Pietu

INSERM U.143, Hopital de Bicetre, le Kremlin-Bicetre, France.

Type IIA and IIB von Willebrand disease (vWD) result from qualitative abnormalities of von Willebrand factor (vWF) characterized by an absence in plasma of high molecular weight vWF multimers and an abnormal reactivity of vWF towards platelet glycoprotein (GP) Ib, which is decreased in type IIA and increased in type IIB. In this report, we describe the case of a patient having a IIA vWD phenotype associated with an intermittent thrombocytopenia atypical in this subtype but observed in type IIB vWD. The patient plasma vWF showed an absence of high molecular weight and intermediate multimers and had a decreased binding capacity to GPIb. The affinity of botrocetin was normal for plasma vWF from the propositus. Analysis of the propositus vWF gene showed the presence of a substitution Val 551 to Phe of the mature vWF subunit. This mutation is localized within a 509-695 disulphide loop of the vWF that plays an important role in the binding to GPIb and is where most of the molecular defects described so far were associated with type-IIB vWD. We have reproduced the Val 551 Phe substitution onto the vWF cDNA, expressed it in COS-7 cells, and performed structural and functional analysis of the mutant recombinant protein (rvWFPhe 551). The rvWFPhe 551 had a normal multimeric structure and showed the capacity to spontaneously interact with GPIb. Botrocetin had a decreased affinity for rvWFPhe 551. In conclusion, the Val 551 Phe mutation modifies the affinity of vWF for platelet GPIb, as does a type IIB mutation, and may be responsible for the thrombocytopenia of the patient and the clearance of the high molecular weight and intermediate- sized multimers of vWF from the plasma. The study of the rvWFPhe 551 has confirmed the discrepancy between the IIA phenotype and the IIB genotype of the patient.

Volume 83, Issue 3, pp. 833-841, 02/01/1994
Copyright © 1994 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A.-S. Ribba, L. Hilbert, J.-M. Lavergne, E. Fressinaud, C. Boyer-Neumann, C. Ternisien, I. Juhan-Vague, J. Goudemand, J.-P. Girma, C. Mazurier, et al.
The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor
Blood, February 15, 2001; 97(4): 952 - 959.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Ajzenberg, A.-S. Ribba, G. Rastegar-Lari, D. Meyer, and D. Baruch
Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation
Blood, June 15, 2000; 95(12): 3796 - 3803.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Matsushita, D. Meyer, and J. E. Sadler
Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin by Charged-to-Alanine Scanning Mutagenesis
J. Biol. Chem., April 6, 2000; 275(15): 11044 - 11049.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. V. Jenkins, K. J. Pasi, and S. J. Perkins
Molecular Modeling of Ligand and Mutation Sites of the Type A Domains of Human von Willebrand Factor and Their Relevance to von Willebrand's Disease
Blood, March 15, 1998; 91(6): 2032 - 2044.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Lankhof, C. Damas, M. E. Schiphorst, M. J.W. IJsseldijk, M. Bracke, J. J. Sixma, T. Vink, and P. G. de Groot
Functional Studies on Platelet Adhesion With Recombinant von Willebrand Factor Type 2B Mutants R543Q and R543W Under Conditions of Flow
Blood, April 15, 1997; 89(8): 2766 - 2772.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Matsushita and J. E. Sadler
Identification of Amino Acid Residues Essential for von Willebrand Factor Binding to Platelet Glycoprotein Ib
J. Biol. Chem., June 2, 1995; 270(22): 13406 - 13414.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1994 by American Society of Hematology         Online ISSN: 1528-0020